We're developing a gamechanger in the world of injectables.
|
|
The next generation
of injectables is here.
With our patented DART™ (Dual Action Rejuvenating Technology)1, we've combined the instant lifting effects of HA (hyaluronic acid) and lasting collagen stimulating CaHA (calcium hydroxyapatite) into one convenient injectable.2,3
Your patients will see both instant and lasting, natural-looking results, with skin that looks refreshed, rejuvenated, rested and revitalized.4,5 All in a ready-to-use injectable that's mild and well-tolerated for minimal downtime after treatment.6
|
|
The patient profile
Designed for patients with facial skin laxity, HArmonyCa® offers a comprehensive approach that provides regenerative collagen stimulation for firmer skin.*,†,‡,§,3
|
|
|
Visit Allergan Direct or reach out to your
Allergan rep to order the revolutionary new,
Dual Action HArmonyCa today.
|
The science behind HArmonyCa®
HArmonyCa® combines CaHA with HA in one
dual-action injectable, delivered in a single treatment
into the deep dermal and sub-dermal layers.1
|
|
HA particles diffuse between collagen fibres of the lower dermal layer for an immediate lifting effect.*5
|
CaHA stimulates the skin to produce collagen.7
|
|
|
|
With Brilliant Distinctions, your first patients to receive HArmonyCa can save. Enrol your patients now so they can be first in line and enjoy other great perks.
|
|
|
You received this email because you signed up to receive communications from Allergan Aesthetics, and AbbVie Corporation division (“AbbVie”). If you no longer wish to receive communications from Allergan Aesthetics, you may withdraw your consent at any time by emailing MKH-Customer-OptOut@allergan.com.
Allergan Aesthetics, an AbbVie company,
1380 Rodick Road, Suite 300, Markham, ON L3R 4G5
© 2023 AbbVie. All rights reserved.
CA-HAR-260043
|
|
|
* Results from a prospective and non-randomized interventional study where HArmonyCa® was injected in the preauricular region of 15 women.
The primary endpoint was the volumetric changes at Day 180. Secondary endpoints included changes in facial tension vectors, time to filler tissue integration, and safety profile.4
† Ultrasound and elastography examinations were performed using the Samsung HT 30 ultrasound machine and the ElastoScan HS30/XH30 respectively (Samsung Healthcare Global). When compared to baseline, an increase in density, viscoelasticity, and firmness of the tissue was observed at 60 days and then confirmed at 90 days after treatment. At 180 days after treatment, an increase in collagen in the treated areas was confirmed.4
‡ Vectra® H2 (Canfield Scientific, Inc.) was used to assess skin lift and tightening by measuring the changes in FTV at 60, 90, and 180 days after treatment. As compared to pre-treatment values, FTV significantly increased at all timepoints with a median (interquartile range) increase of 2.2 (1.6-2.2) mm and 2.0 (1.7-2.2) mm in the right and left side, respectively (p<0.0001 each), 180 days after treatment.4
§ The responses of N=75 physicians when asked What signs of ageing indicate the greatest suitability.
1. Data on file. DART trademark.
2. Gritti A, et al. J Cosmet Dermatol. 2025;24(9):e70430.
3. Urdiales-Gálvez F, et al. J Cosmet Dermatol. 2023;22(8):2186-2197.
4. Allergan Aesthetics. HArmonyCa® Lidocaine DFU. November 14, 2025.
5. Hee C et al. Dermatol Surg. 2015;41:S373-381
6. Braz A et al. Plast Reconstr Surg Glob Open. 2024;12(2):e5622.
7. Allergan Aesthetics. Data on File. ABVRRTI81261 Comparative Analysis of Bio-Stimulatory Effects. REF-139077.
|
